Market Size of Global Hyperlipidemia Drugs Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 2.30 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Hyperlipidemia Drugs Market Analysis
The hyperlipidemia drugs market is expected to register a CAGR of 2.3% during the forecast period.
The healthcare system witnessed enormous challenges as a result of the COVID-19 pandemic. All outpatient treatments were postponed or restricted during the COVID-19 pandemic to reduce the risk of viral transmission as most chronic therapies were regarded as non-urgent. However, the intake of hyperlipidemia drugs in COVID-19-affected patients reduced the severity of the infection. According to a report by UC San Diego Health published in July 2021, intake of statin medications had a 41% lower risk of in-hospital death from COVID-19. Also, the report indicated that the use of statins or an anti-hypertension medication was associated with a 32% lower risk of death among COVID-19 in patients with a history of cardiovascular disease or hypertension. Such factors helped in the market growth during the COVID-19 pandemic.
The hyperlipidemia drug market is growing at a good rate attributing to an increase in the target population and growth in awareness about risk of cardiovascular diseases (CVD) due to persistent hypercholesterolemia. The American Heart Association in its 2022 update on Heart Disease and Stroke Statistics showed that in 2020, around 19.05 million deaths were reported globally because of cardiovascular diseases.
Several product launches is also anticipated to drive the hyperlipidemia drugs market. For instance, In December 2021, the United States Food and Drug Administration approved Leqvio (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C) with two doses a year. Such approvals are likely to aid in the market growth.
However, the upcoming patent expiration of drugs and the regulatory frameworks are expected to slow down the market growth over the forecast period.
Hyperlipidemia Drugs Industry Segmentation
As per the scope of this report, hyperlipidemia is a condition that is caused by abnormally high lipid levels in the blood and it is the most common type of dyslipidemia. This disorder can happen due to genetic factors (primary hyperlipidemia) as well as other factors such as unhealthy lifestyle and poor diet (secondary hyperlipidemia). Statins are the first line of treatment for secondary hyperlipidemia. The hyperlipidemia market is segmented by drug class (statins, cholesterol absorption inhibitors, bile acid sequestrants, pcsk9 inhibitors, others), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers the value in USD million for the above segments.
| By Drug Class | |
| Statins | |
| Cholesterol Absorption Inhibitors | |
| Bile Acid Sequestrants | |
| PCSK9 Inhibitors | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Hyperlipidemia Drugs Market Size Summary
The hyperlipidemia drugs market is poised for steady growth, driven by an increasing awareness of cardiovascular disease risks associated with persistent hypercholesterolemia and a rising target population. The market's expansion is further supported by recent product launches and regulatory approvals, such as the FDA's approval of Leqvio, a novel therapy for lowering LDL cholesterol. Despite challenges posed by patent expirations and regulatory frameworks, the market is expected to benefit from ongoing clinical trials and research focused on statin treatments and other therapies aimed at reducing cardiovascular risk. Statins, in particular, are anticipated to maintain a strong presence in the market due to their effectiveness in reducing heart attack risks and their role in improving endothelial function and reducing inflammation.
North America is projected to hold a significant share of the global hyperlipidemia drugs market, attributed to the high prevalence of hypercholesterolemia, substantial healthcare expenditure, and a robust healthcare infrastructure. The region's growing obese population, coupled with increased diagnostic adoption of hyperlipidemia drugs, is expected to further propel market growth. The United States, in particular, is witnessing a rise in healthcare spending, which is anticipated to boost market demand. The market is characterized by intense competition, with major players like Dr. Reddy's Laboratories, Viatris Inc., Amgen, Sanofi, AstraZeneca, and Merck & Co., Inc. leading the charge. Recent approvals and recommendations for new therapies, such as bempedoic acid, are expected to enhance market dynamics and drive growth over the forecast period.
Global Hyperlipidemia Drugs Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Growth in Awareness About Risk of Cardiovascular Diseases
-
1.2.2 Emergence of Novel Drug Classes
-
1.2.3 Rise in Prevalence of Hyperlipidemia Across the Globe
-
-
1.3 Market Restraints
-
1.3.1 Upcoming Patent Expirations of Drugs
-
1.3.2 Regulatory Framework
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - in USD Millions)
-
2.1 By Drug Class
-
2.1.1 Statins
-
2.1.2 Cholesterol Absorption Inhibitors
-
2.1.3 Bile Acid Sequestrants
-
2.1.4 PCSK9 Inhibitors
-
2.1.5 Others
-
-
2.2 Geography
-
2.2.1 North America
-
2.2.1.1 United States
-
2.2.1.2 Canada
-
2.2.1.3 Mexico
-
-
2.2.2 Europe
-
2.2.2.1 Germany
-
2.2.2.2 United Kingdom
-
2.2.2.3 France
-
2.2.2.4 Italy
-
2.2.2.5 Spain
-
2.2.2.6 Rest of Europe
-
-
2.2.3 Asia-Pacific
-
2.2.3.1 China
-
2.2.3.2 Japan
-
2.2.3.3 India
-
2.2.3.4 Australia
-
2.2.3.5 South Korea
-
2.2.3.6 Rest of Asia-Pacific
-
-
2.2.4 Middle-East and Africa
-
2.2.4.1 GCC
-
2.2.4.2 South Africa
-
2.2.4.3 Rest of Middle-East and Africa
-
-
2.2.5 South America
-
2.2.5.1 Brazil
-
2.2.5.2 Argentina
-
2.2.5.3 Rest of South America
-
-
-
Global Hyperlipidemia Drugs Market Size FAQs
What is the current Global Hyperlipidemia Drugs Market size?
The Global Hyperlipidemia Drugs Market is projected to register a CAGR of 2.30% during the forecast period (2024-2029)
Who are the key players in Global Hyperlipidemia Drugs Market?
Merck & Co., Inc, Sanofi, Amgen, AstraZeneca and Viatris Inc. are the major companies operating in the Global Hyperlipidemia Drugs Market.
